Efficacy and safety of hexaprenaline in pregnant women at risk of premature birth: the effect of polymorphism of the ADRB2 gene

DOI: https://doi.org/10.29296/25877305-2021-08-10
Download full text PDF
Issue: 
8
Year: 
2021

G. Proklova(1); Associate Professor R. Chilova(1), MD; Associate Professor E. Sokova(1, 2),
Candidate of Medical Sciences; R. Kazakov(2), Candidate of Biological Sciences; E. Zhukova(1), Candidate of
Medical Sciences; K. Akopov(3); O. Pobedinskaya(1), Candidate of Medical Sciences (1)I.M. Sechenov First
Moscow State Medical University (Sechenov University), Ministry of Health of Russia (2)Research Center for
Examination of Medical Products, Ministry of Health of Russia, Moscow (3)S.S. Yudin City Clinical Hospital,
Branch, Female Counseling Center Three, Moscow

Hexoprenaline has been shown to be an effective tocolytic drug in pregnant women at risk for premature birth (PB). The efficacy and safety of hexoprenaline are affected by the ADRB2 gene polymorphisms, including missense mutations associated with Gly16Arg and Gln27Glu substitutions, which can perform a protective function and affect predisposition to PB. Objective: to analyze the impact of the ADRB2 gene polymorphisms on the risk for PB as well as the efficiency and safety of tocolytic pharmacotherapy with hexoprenaline in pregnant women at risk for PB. Subjects and methods. The investigation involved 120 pregnant women. A study group included 60 patients at risk for PB who received tocolytic therapy with hexoprenaline. A control group consisted of women who had given birth to full-term children (at 37–41 weeks) and did not have a need for tocolytic therapy during pregnancy. The Gly16Arg and Gln27Glu polymorphism in the ADRB2 gene was determined in all the study participants, by using polymerase chain reaction-restriction fragment length polymorphism. The findings were compared with the indicators of the efficacy and safety of hexoprenaline. Results. The pregnant women at risk for PB were shown to have the 16Arg allele significantly less commonly (p=0.028) and the 16Gly/Gly genotype in the ADRB2 gene significantly more commonly (p=0.027). The efficacy of hexoprenaline was lower in the carriers of the genotypes indicating the high or low expression of β2-adrenoreceptors. 53% of pregnant women had adverse hexoprenaline reactions: tachycardia (47%) and headache (6%). Their incidence was unassociated with the ADRB2 gene polymorphism.
Keywords: 
obstetrics and gynecology
hexoprenaline
genotyping
tocolytic therapy
preterm birth
single nucleotide polymorphisms
ADRB2

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Blencowe H., Cousens S., Oestergaard M.Z. et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. Lancet. 2012; 379 (9832): 2162–72. DOI: 10.1016/S0140-6736(12)60820-4
  2. Serov V.N., Tjutjunnik V.L. Taktika lechenija ugrozhajuschih prezhdevremennyh rodov. RMZh. 2008; 16 (19): 1252–5 [Serov V.N., Tyutyunnik V.L. Tactics for the treatment of threatened premature birth. RMJ. 2008; 16 (19): 1252–5 (in Russ.)].
  3. Cagliani R., Fumagalli M., Pozzoli U. Et al. Diverse evolutionary histories for beta-adrenoreceptor genes in humans. Am J Hum Genet. 2009; 85 (1): 64–75. DOI: 10.1016/j.ajhg.2009.06.005
  4. Cheslack-Postava K., Fallin M.D., Avramopoulos D. et al. β2-Adrenergic receptor gene variants and risk for autism in the AGRE cohort. Molecular Psychiatry. 2007; 12: 283–91. DOI:10.1038/sj.mp.4001940
  5. Diatchenko L., Anderson A.D., Slade G.D. et al. Three major haplotypes of the β2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B (5): 449–62. DOI: 10.1002/ajmg.b.30324
  6. Schürks M., Kurth T., Ridker P.M. et al. Association between polymorphisms in the β2-adrenergicreceptor gene with myocardial infarction and ischemic stroke in women. Thromb Haemost. 2009; 101 (2): 351–8.
  7. Ozkur M., Dogulu F., Ozkur A. et al. Association of the Gln27Glu polymorphism of the beta-2-adrenergic receptor with preterm labor. Int J Gynaecol Obstet. 2002; 77: 209–15. DOI: 10.1016/s0020-7292(02)00035-8
  8. Kunihiko D., Istvan S., Santosh V. et al. β2-Adrenergic receptor gene polymorphisms and pregnancy outcome. J Perinatal Med. 2004; 32: 413–7.
  9. Landau R., Morales M.A., Antonarakis S.E. et al. Arg16 homozygosity of the beta-2 adrenergic receptor improves the outcome after beta-2 agonist tocolysis for preterm labor. Clin Pharmacol Ther. 2005; 78: 656–63. DOI: 10.1016/j.clpt.2005.08.021
  10. Park J.Y., Lee N.R., Lee K.E. Effects of β2-Adrenergic Receptor Gene Polymorphisms on Ritodrine Therapy in Pregnant Women with Preterm Labor: Prospective Follow-Up Study. Int J Mol Sci. 2014; 15: 12885–94. DOI: 10.3390/ijms150712885
  11. Surina M.N., Chvanova E.A. Techenie beremennosti i ee ishody u patsientok s defitsitom massy tela. Fundamental'naja i klinicheskaja meditsina. 2018; 3 (3): 65–70 [Surina M.N., Chvanova E.A. Pregnancy course and outcomes in women with low body mass index. Fundamental and Clinical Medicine. 2018; 3 (3): 65–70 (in Russ.)]. DOI: 10.23946/2500-0764-2018-3-3-65-70
  12. Miller R.S., Smiley R.M., Daniel D. et al. Beta-2 adrenoceptor genotype and progress in term and late preterm active labor. Am J Obstet Gynecol. 2011; 205 (2): 137.e1–137.e7. DOI: 10.1016/j.ajog.2011.03.045